Evidence map›Paper›PMID 31718000›Full record

ArticleBiomolecules2019

The Novel Serine/Threonine Protein Kinase LmjF.22.0810 from

Andrés Vacas, Celia Fernández-Rubio, Miriam Algarabel, José Peña-Guerrero, Esther Larrea, Fabio Rocha Formiga, Alfonso T García-Sosa, Paul A Nguewa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. EXCLI journal · 2024
    Article
  2. Genome deletions to overcome the directed loss of gene function inFrontiers in cellular and infection microbiology · 2022
    Article
  3. InInternational journal of molecular sciences · 2021
    Article
  4. Microorganisms · 2021
    Review
  5. LmjF.22.0810 fromBiomedicines · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Andrés VacasDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
Celia Fernández-RubioDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
Miriam AlgarabelDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
José Peña-GuerreroDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
Esther LarreaDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
Fabio Rocha FormigaAggeu Magalhães Institute, Oswaldo Cruz Foundation (FIOCRUZ). Graduate Program in Applied Cellular and Molecular Biology (BCMA), University of Pernambuco (UPE), Recife/PE 50.670-420, Brazil.
Alfonso T García-SosaInstitute of Chemistry, University of Tartu, Ravila 14a, Tartu 54011, Estonia.
Paul A NguewaDepartment of Microbiology and Parasitology, ISTUN Institute of Tropical Health, University of Navarra, IdiSNA (Navarra Institute for Health Research). Pamplona, E-31008 Navarra, Spain.
Universidad de Navarra · ESFundação Oswaldo Cruz · BRUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification and clarification of the mechanisms of action of drugs used against leishmaniasis may improve their administration regimens and prevent the development of resistant strains. Herein, for the first time, we describe the structure of the putatively essential Ser/Thr kinase LmjF.22.0810 from

Indexed as

Antiprotozoal AgentsDrug ResistanceHumansLeishmania majorLeishmaniasis, CutaneousMolecular Dynamics SimulationParomomycinProtein Serine-Threonine KinasesAntiprotozoal AgentsParomomycinProtein Serine-Threonine Kinasesdockingdrug resistancekinaseLeishmaniaLmJean3LmjF.22.0810molecular dynamicsNTDparomomycintreatment

Identifiers

PMID31718000
PMCPMC6920834
OpenAlexW2982859962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.